As a universal way of immunotherapy, ICB treatment has made conducive progress, which aims to facilitate immune surveillance and target specific immune checkpoints, such as PD-L1 and CTLA4, which are widely used for HCC therapy [52]. The gene discussed is CD274; the disease is hepatocellular carcinoma.